Overview
- Haleon trimmed its full-year organic revenue growth guidance to about 2.5% on Thursday after third-quarter organic sales rose 2.6%, missing analyst expectations.
- The company said softer demand for cough, cold and flu products reduced orders in North America and was the main driver of the quarterly shortfall.
- Haleon suspended shipments of Centrum multivitamins into China after a change in raw-material classification constrained over-the-counter imports and hurt sales there.
- Management warned the decision to accelerate a new go-to-market model in Brazil to align with a local tax change will cost an estimated £15–20 million of net revenue in the fourth quarter.
- Oral-health brands and mid-single-digit growth in emerging markets, led by India, partly offset weakness but the update sent shares down more than 11% in early trading and raised investor focus on seasonal and regulatory risks.